{"id":"nefecon","safety":{"commonSideEffects":[{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nefecon is a novel formulation combining the corticosteroid budesonide with a carrier system designed to target drug delivery to the kidney. It works by locally suppressing immune-mediated inflammation in the glomeruli, specifically addressing the pathogenic IgA immune complex deposition characteristic of IgA nephropathy, while minimizing systemic corticosteroid exposure and associated side effects.","oneSentence":"Nefecon is a targeted immunosuppressant that delivers budesonide directly to the kidney to reduce inflammation in IgA nephropathy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:19.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"IgA nephropathy with risk of progression to end-stage renal disease"}]},"trialDetails":[{"nctId":"NCT06712407","phase":"PHASE4","title":"Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy","status":"RECRUITING","sponsor":"Calliditas Therapeutics AB","startDate":"2024-12-17","conditions":"IgA Nephropathy","enrollment":60},{"nctId":"NCT06676007","phase":"","title":"A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-10-30","conditions":"IgA Nephropathy (IgAN), Early Initial Therapy","enrollment":200},{"nctId":"NCT07030894","phase":"PHASE4","title":"Nefecon and Ambrisentan in IgA Nephropathy","status":"RECRUITING","sponsor":"The First Hospital of Jilin University","startDate":"2025-09-01","conditions":"IgA Nephropathy, Chronic Kidney Disease, Proteinuria","enrollment":129},{"nctId":"NCT04541043","phase":"PHASE3","title":"Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301 (Nefigard-OLE)","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2020-11-17","conditions":"Primary IgA Nephropathy","enrollment":119},{"nctId":"NCT03643965","phase":"PHASE3","title":"Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2018-09-05","conditions":"Primary IgA Nephropathy","enrollment":365},{"nctId":"NCT05534919","phase":"PHASE3","title":"Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301","status":"COMPLETED","sponsor":"Everest Medicines (Singapore) Pte. Ltd.","startDate":"2022-12-09","conditions":"Primary Immunoglobulin a Nephropathy (IgAN)","enrollment":21},{"nctId":"NCT01738035","phase":"PHASE2","title":"The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2012-12","conditions":"Primary IgA Nephropathy","enrollment":150},{"nctId":"NCT00767221","phase":"PHASE2","title":"Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study","status":"COMPLETED","sponsor":"Calliditas Therapeutics AB","startDate":"2005-10","conditions":"IGA Nephropathy","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":36,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Budesonide modified-released capsules (4 mg/capsule)","Budesonide modified released capsule"],"phase":"phase_3","status":"active","brandName":"NEFECON","genericName":"NEFECON","companyName":"Calliditas Therapeutics AB","companyId":"calliditas-therapeutics-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nefecon is a targeted immunosuppressant that delivers budesonide directly to the kidney to reduce inflammation in IgA nephropathy. Used for IgA nephropathy with risk of progression to end-stage renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}